Rapivab (Intravenous)

Rapivab (Intravenous) Uses, Dosage, Side Effects, Food Interaction and all others data.

Rapivab (Intravenous) is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days.

Rapivab (Intravenous)
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Rapivab (Intravenous)
Availability	Prescription only
Generic	Peramivir
Peramivir Other Names	Peramivir
Related Drugs	amantadine, Tamiflu, oseltamivir, Vicks DayQuil Severe Cold & Flu, Xofluza, Coricidin HBP Cold & Flu
Type
Formula	C₁₅H₂₈N₄O₄
Weight	Average: 328.4072 Monoisotopic: 328.211055404
Groups	Approved, Investigational
Therapeutic Class
Manufacturer
Available Country	USA
Last Updated:	September 19, 2023 at 7:00 am

Uses

Rapivab (Intravenous) is an intravenous antiviral agent used to treat acute uncomplicated influenza in patients aged 2 years and older who are shown to be symptomatic for no more than two days.

Indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days.

Rapivab (Intravenous) is also used to associated treatment for these conditions: Acute, uncomplicated Influenza